In Vivo's Rough Guide On The State Of RNAi
How Will RNA Modalities Stack Up Against Gene Therapy?
Executive Summary
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. In Vivo reviews the leading drug developers in this space.
You may also be interested in...
J.P. Morgan Notebook Day 1: No Big Deals, But Plenty Of Pipeline, Commercial Highlights
Daily round-up from the J.P. Morgan Healthcare Conference in San Francisco: There was no big M&A, but biopharma CEOs discussed deals they're pursuing. Also, Novartis's Zolgensma reimbursement insights, Sarepta's third DMD filing, Bristol's post-merger progress and more highlights.
Novartis Inks World-First Pact With NHS England For Inclisiran
The innovative collaboration should accelerate access to the first-in-class cholesterol lowering drug acquired with The Medicines Company buy.
Alnylam Interview: RNAi Leader Expands Into NASH, CNS And Eye Diseases
Feature article: Alnylam’s R&D leader Akshay Vaishnaw sets out plans for next-generation gene-silencing therapies.